Beranda › Nefritis Lupus
Uji klinis Nefritis Lupus yang merekrut di AS
33 studi untuk Nefritis Lupus merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- New York City, NY10 studi
- Chicago, IL9 studi
- Atlanta, GA9 studi
- Houston, TX8 studi
- Durham, NC8 studi
- San Francisco, CA7 studi
- Boston, MA7 studi
- Philadelphia, PA7 studi
- Aurora, CO5 studi
- St. Louis, MO5 studi
- Miami, FL5 studi
- Charleston, SC4 studi
- Charlotte, NC4 studi
- Dallas, TX4 studi
- Cleveland, OH4 studi
- Los Angeles, CA4 studi
- Syracuse, NY4 studi
- Johns Creek, GA3 studi
- Baltimore, MD3 studi
- Jacksonville, FL3 studi
- New Orleans, LA3 studi
- Washington, DC3 studi
- Columbus, OH3 studi
- Santa Monica, CA3 studi
- Worcester, MA3 studi
- Gainesville, FL3 studi
Berdasarkan negara bagian
- Arizona3 studi
- California15 studi
- Colorado7 studi
- Florida11 studi
- Georgia11 studi
- Illinois9 studi
- Kansas3 studi
- Louisiana5 studi
- Maryland5 studi
- Massachusetts8 studi
- Michigan3 studi
- Minnesota3 studi
- Missouri6 studi
- New Jersey5 studi
- New York16 studi
- North Carolina11 studi
- Ohio7 studi
- Pennsylvania7 studi
- South Carolina5 studi
- Tennessee4 studi
- Texas12 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Menerima pesertaFase 2
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06419205Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05268289Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06711887CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Menerima pesertaFase 1/2
Usia 10 hingga 29 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Menerima pesertaFase 2
Usia 16 hingga 70 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07328581Study of Systemic Lupus Erythematosus
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 3 hingga 120 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT00001372VIBRANT: VIB4920 for Active Lupus Nephritis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05201469Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Menerima pesertaFase 1
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Menerima pesertaFase 2
Usia 8 hingga 20 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Menerima pesertaFase 2
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07570862A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Menerima pesertaFase 1
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07085104A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06897930A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Menerima pesertaFase 2
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05039619A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Menerima pesertaFase 1/2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Menerima pesertaFase 2
Usia 12 hingga 65 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT07053800PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Menerima pesertaFase 4
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07611214A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Wanita · Diperbarui 24 Jul 2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06527872US Zamto-cel Autoimmune Diseases
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT06708845A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT06557265Dapagliflozin in Active Lupus Nephritis
Menerima pesertaFase 4
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT07323524A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Menerima pesertaFase 1
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06308978Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.